Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2024 | $235.00 | Buy | Redburn Atlantic |
5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
10/2/2023 | $260.00 → $240.00 | Hold → Buy | Jefferies |
8/21/2023 | $320.00 → $219.00 | Outperform → Neutral | Robert W. Baird |
8/21/2023 | $273.00 → $265.00 | Neutral → Buy | Citigroup |
5/30/2023 | $343.00 | Equal-Weight | Morgan Stanley |
Label expansion makes Omnipod 5 commercially available to 6 million people living with insulin-requiring type 2 diabetes Omnipod 5 is the first and only automated insulin delivery (AID) system indicated for both type 1 and type 2 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management. "Today's annou
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024 at 8:30 a.m. The Baird 2024 Global Healthcare Conference in New York City on Tuesday, September 10, 2024 at 8:30 a.m. To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts
Global tubeless insulin pump technology leader officially commences manufacturing of Omnipod® 5 Automated Insulin Delivery System at new facility, enabling continued worldwide customer growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240813627828/en/Insulet President and CEO Jim Hollingshead, senior leaders, and local employees celebrate the official grand opening of the new
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today's announcement concludes an extensive search process conducted by the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320426712/en/Ana Maria Chadwick, Chief Financial Officer (Photo: Business Wire) "We are thrilled to welcome Ana to Insulet," said Jim Hollingshead, President and Chief Executive Officer. "She is an ex
10-Q - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
Raising Full Year Revenue, Gross Margin and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr
Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report full second quarter 2024 financial results on August 8, 2024, as planned, and host a conference call that day at 4:30 p.m. (Eastern Time). Preliminary Second Quarter Revenue Highlights: Second quarter 2024 revenue of $488 million, up 23%, compared to $397 million in the prior year, exceeds the guidance range of
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Redburn Atlantic initiated coverage of Insulet with a rating of Buy and set a new price target of $235.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $200.00
Robert W. Baird upgraded Insulet from Neutral to Outperform and set a new price target of $238.00 from $180.00 previously
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
In the preceding three months, 7 analysts have released ratings for Insulet (NASDAQ:PODD), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 2 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $225.14, along with a high estimate of $260.00 and a low estimate of $200.00. Highlig
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and maintains $234 price target.
Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 12.29% on an annualized basis producing an average annual return of 24.43%. Currently, Insulet has a market capitalization of $13.66 billion. Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 15 years ago, it would be worth $26,248.99 today based on a price of $195.03 for PODD at the time of writing. Insulet's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)